

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-61) VOPRATELIMAB
 PRONUNCIATION voe" pra tel' i mab
 THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(inducible T-cell costimulator)(humanized monoclonal JTX-2011 γ 1-chain), disulfide with humanized monoclonal JTX-2011 κ -chain, dimer
2. Immunoglobulin G1-kappa, anti-(*Homo sapiens* inducible T-cell costimulator (antigen CD278)); humanized monoclonal antibody; γ 1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-74*01 (89%) –(IGHD)-IGHJ5*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 {CH1[R⁹⁷>K(214)]} (118-447) (220-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (84%) –IGKJ3*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')], dimer (226-226":229-229")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain					
EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	DYWMDWVRQA	PGKGLVWVSN	50
IDEDGSITEY	SPFVKGRFTI	SRDNAKNTLY	LQMNSLRAED	TAVYYCTRWG	100
RFQFDSWGQG	TLVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	ALGCLVKDYF	150
PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS	SSLGTQTYIC	200
NVNHKPSNTK	VDKKEPKKSC	DKHTCPCPCP	APELLGGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	300
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	350
LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTTPVLDS	400
DGSFFLYSKL	TVDKSRWQQG	NVFSCSVMHE	ALHNHYTQKS	LSSLSPGK	447
Light chain					
DIVMTQSPDS	LAVSLGERAT	INCKSSQSL	SGSFNYLTWY	QQKPGQPPKL	50'
LIFYASTRHT	GVPDRFSGSG	SGTDFTLTIS	SLQAEDVAVY	YCHHHYNAPP	100'
TFGPGTKVDI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPREAKV	150'
QWKVDNALQS	GNSQESVTEQ	DSKDSYISLS	STLTLSKADY	EKHKVYACEV	200'
THQGLSSPVT	KSFNRGEC				218'

Disulfide bridges							
22-96	22"-96"	23'-92'	23'''-92'''	138'-198'	138'''-198'''	144-200	144"-200"
218-220	218"-220"	226-226"	229-229"	261-321	261"-321"	367-425	367"-425"

Glycosylation sites (N)
 Asn-297 Asn-297"

MOLECULAR FORMULA C₆₄₈₈H₉₉₈₆N₁₇₂₆O₂₀₁₄S₄₄ (unglycosylated)

MOLECULAR WEIGHT 145.8 kDa (unglycosylated)

TRADEMARK None as yet

SPONSOR	Jounce Therapeutics
CODE DESIGNATIONS	JTX-2011
<u>CAS</u> REGISTRY NUMBER	2039148-04-2
UNII	QXN20J93AH
WHO NUMBER	10730

gbk